BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15058791)

  • 1. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS; Finlay AY; Lewis JJ; Sumner MI
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
    Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
    Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life.
    Karamata VV; Gandhi AM; Patel PP; Sutaria A; Desai MK
    Indian J Pharmacol; 2017; 49(1):84-88. PubMed ID: 28458428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
    Reitamo S; Spuls P; Sassolas B; Lahfa M; Claudy A; Griffiths CE;
    Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
    Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
    Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM; Bardazzi F; Tosti A; Varotti C
    Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
    Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
    J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.